Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Bristol Myers Squibb Co. (BMY), Ariad Pharmaceuticals, Inc. (ARIA): ASCO Investment Ideas

Page 1 of 2

The American Society of Clinical Oncology annual meeting kicks off today. The scientific conference is the premier place for oncology companies to present data on their cancer drugs. Here are a couple of investment ideas for cancer stocks to watch during the meeting.

Big pharma, big movers
We don’t usually associate ASCO investment ideas with big pharma. Sure, they present data each year, but it’s hard to identify an investment idea that will actually move a pharma’s stock, given their large size. It takes a lot to move the needle.

Bristol Myers Squibb Co. (NYSE:BMY)

This year looks like it’ll be different. Bristol Myers Squibb Co. (NYSE:BMY) and Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) both have drugs that look like they can be mega blockbusters because their compounds can potentially be used to treat multiple types of cancer.

Rather than attacking the cancer directly, where different types of cancer require different targets, Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY)’s MPDL3280A and Bristol Myers Squibb Co. (NYSE:BMY)’s nivolumab remove a molecular switch that holds back the immune system from attacking the cancer. Both drugs turn off the switch, allowing the immune system to attack the cancer.

I don’t necessarily think this mechanism is the cure for cancer, but it does appear to help in a wide range of tumors that all use the same switch to tell the immune system not to attack.

Expanding possibilities
Exelixis, Inc. (NASDAQ:EXEL) announced today that it started a phase 3 trial for Cometriq for patients with kidney cancer  The trial will enroll patients who have failed a first-line treatment such as Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)‘s  Nexavar or Pfizer Inc. (NYSE:PFE)‘s Sutent. Going for the second-line indication is less risky although it cuts down on the market size a bit.

I doubt the timing of the announcement is a coincidence. Exelixis, Inc. (NASDAQ:EXEL) has nine different presentations at ASCO covering Cometriq in different indications. The drug is already approved to treat medullary thyroid cancer that has spread to other parts of the body, but that’s a small indication that only affects 500 to 700 patients in the U.S. each year.

Exelixis really needs to expand Cometriq into other indications. Kidney cancer is a good choice and Exelixis is also testing it in prostate cancer. One of the presentations featured at ASCO is an update from its phase 2 prostate cancer trial.

A blood cancer
ASCO is typically about solid tumors while the American Society of Hematology annual meeting focuses on blood cancers like leukemia and lymphoma, but Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is out in full force with seven presentations for Iclusig.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!